Page 1of [ADDRESS_1026642] Lenses
Protocol Number:
Development Stage of 
Project:
Sponsor Name [CONTACT_13311]:
Test Product:
Investigator Agreement:CLC127-C 001 / [STUDY_ID_REMOVED]
Development
Alcon
 Research, Ltd. and i
ts affiliates (“Alcon”)
[ADDRESS_1026643] 
lenses ( LID009941)
I have read the clinical study described herein,  and recognize its 
confidentiality . I
 agree to conduct this study in accordance with 
the ethical principles contained within the Declaration of 
Helsinki, and the described study
 in compliance with the 
protocol, Good Clinical Practice (GCP), I SO [ZIP_CODE], and all 
applicable regulatory requirements. Additionally , I will comply 
with all procedures for data recording and reporting, will permit 
monitoring, auditin
g, and inspection of my research center, and 
will retain all records until notified by [CONTACT_750155] r.
Principal I nvestigator:
Signature [CONTACT_40073]:
Address:
Template version 1.0, approved 09JUNE 2017
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026644] OF ACRONYMS AND ABBREVIA TIONS ...........................................................10
3PROT OCOL  SUMMAR Y
................................................................................................. 11
4PROT OCOL  AMENDMENTS .........................................................................................18
4.1 Amendments ......................................................................................................19
5INTRODUCTION .............................................................................................................19
5.1 Rationale and Background ................................................................................19
5.2 Purpose of the Study ..........................................................................................20
5.3
Risks and Benefits .............................................................................................20
6STUDY  OBJECTI VES ................................ ................................ ................................ ......21
6.1 Primary  Objective(s) .........................................................................................21
6.2 Secondary  Objective(s)
.....................................................................................21
22
6.4 Safety  
Objective(s) ............................................................................................22
7INVESTIGA TIONAL  PLAN ............................................................................................22
7.1 Study  Design .....................................................................................................22
7.2 Rationale for Study  Design ...............................................................................23
7.3 Rationale for Duration of Treatment/Follow -Up...............................................[ADDRESS_1026645](s) ................................ ................................ ..................26
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017

Page 3of 54
9.2 Other Medical Device or Medication Specified for Use During the Study ......30
9.3 Treatment Assignment / Randomization ...........................................................30
9.4 Treatment masking ............................................................................................30
9.5 Accountability  Procedures .................................................................................32
9.6
Changes to concomitant medications, treatments/ procedures..........................[ADDRESS_1026646] compliance ..................................................35
10.2.4 Adverse Event Collection: Safety  Assessment ..................................35
10.2.5 Slit-Lamp Biomicroscopy : Safet yAssessment .................................35
10.2.6 Device Deficiencies: Safety  Assessment ...........................................35
10.2.7 Additional Study  Assessments: Ef fectiveness and Safety  Assessments
...........................................................................................................[ADDRESS_1026647] Evaluability ................................ ................................ ...........................44
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Page 4of 54
12.2 Analy sis Sets .....................................................................................................44
12.2.1 Safety  Analysis Set ............................................................................44
12.2.2 Full Anal ysis Set ................................................................................45
12.2.3 Per Protocol Anal ysis Set ..................................................................45
12.3
Demographic and Baseline Characteristics.......................................................45
12.4 Effectiveness Anal yses......................................................................................45
12.4.1 Analy sis of Primary  Effectiveness Endpoint(s) .................................45
[IP_ADDRESS] Statistical Hy potheses ........................................................46
[IP_ADDRESS] Analy sis Methods ..............................................................[ADDRESS_1026648] of Tables
Table2–[ADDRESS_1026649] of Acron yms and Abbreviations Used in This Protocol ...........................10
Table3–1 Schedule of Study  Procedures and Assessments ................................ .............17
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017

Page 5of 54
Table6–1 Primary  Objective(s) ................................ ................................ ........................21
22
Table6–3 Safety  Objective(s) ................................ ................................ ...........................22
Table9–[ADDRESS_1026650] ................................ ................................ ................................ .....26
Table9–[ADDRESS_1026651] ................................ ................................ ................................28
Table9–[ADDRESS_1026652] of Figur es
Figure 7 –1 Flowchart of Study  Visit................................ ................................ ..................23
Figure 11–1 Categorization of All Adverse Events ................................ ..............................38
Figure 11-2 Categorization of All Serious Adverse .............................................................38
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026653](s) Throughout this document, test product will be referred to as 
AOHG toric
Name [CONTACT_69215](s) AIR OPTIX®for Astigmatism soft contact [CONTACT_13276] (AO toric)
Adverse Device Ef fect Adverse event related to the use of a n investigational 
medical device (test product ) or control product. Note: This 
definition includes adverse events r esulting fr om insufficient 
or inadequate instructions for use, deployment, 
implantation, installation, or operation; any malfunction; 
and use err or or intentional misuse of the test pr oduct or 
contr ol pr oduct.
Adverse Event Any untoward medical occurrence, unintended disease or 
injury , or untoward clinical signs (including abnormal 
laboratory  findings) in subjects, users or other persons, 
whether or not related to the investigational medical device 
(test product). Note: For s ubjects, this definition includes 
events r elated to the test pr oduct, the contr ol product, or the 
procedur es involved. For users or other persons, this 
definition is r estricted to events r elated to the test pr oduct.
Requirements for reporting Adverse Event s in the study  can 
be found in Section [ADDRESS_1026654] to its identity , 
quality , durability , reliability , safety , or performance. Note: 
This definition includes malfunctions, use err ors, and 
inadequate labeling.
Requirements for reporting Device Deficiencies in the s tudy 
can be found in Section 1 1.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026655] u d y .
I nter ve nti o nal Cli nical T rial A researc h trial t hat pr os pecti vel y assi g ns, w het her 
ra n d o ml y  or n ot, h u ma n partici pa nts or gr o u ps of h u ma ns t o 
o ne or m ore healt h -relate d i nter ve nti o ns t o e val uate t he 
eff ects o n healt h o utc o mes, a n d/ or a researc h trial i n w hic h 
dia g n ostic or m o nit ori n g pr oce d ures be y o n d sta n dar d of care 
are c o n d ucte d a n d ge nerate o utc o mes f or use i n a nal y sis of 
data. 
I n vesti gati o nal Pr o d uct Is defi ne d as a pre ve ntati ve ( vacci ne), a t hera pe utic ( dr u g or 
bi ol o gic), de vice, dia g n ostic, or palliati ve use d as a test or 
c o ntr ol pr o d uct i n a cli nical trial, i ncl u di n g a pr o d uct wit h a 
mar keti n g a ut h orizati o n w he n use d or asse m ble d 
(f or m ulate d or pac ka ge d) i n a wa y  differe nt fr o m t he 
a ut h orize d f or m, or w he n use d f or a n u na ut h orize d 
i n dicati o n, or w he n use d t o gai n f urt her i nf or mati o n a b o ut 
t he a ut h orize d f or m .
Malf u ncti o n Fail ure of a me dical de vice t o perf or m i n acc or da nce wit h its 
i nte n de d p ur p ose w he n use d i n acc or da nce wit h t he 
i nstr ucti o ns f or use or cli nical i n vesti gati o n pla n. 
N o n -seri o us A d verse E ve nt A d verse e ve nt t hat d oes n ot meet t he criteria f or a seri o us 
a d verse e ve nt. 
Ra n d o mize d S u bjects A n y  s u bjec t w h o is assi g ne d a ra n d o mize d treat me nt. 
Seri o us A d verse De vice 
Ef fect ( S A D E) A d verse de vice ef fect t hat has res ulte d i n a n y of t he 
c o nse q ue nces c haracteristic of a seri o us a d verse e ve nt. 
Seri o us A d verse E ve nt 
( S A E) A d verse e ve nt t h at le d t o a n y  of t he f oll o wi n g: 
Deat h. 
A seri o us deteri orati o n i n t he healt h of t he s u bject 
t hat eit her res ulte d i n: 
a. a life -t hreate ni n g ill ness or i nj ur y .Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 8of 5 4 
N ote: Life -t hr e ate ni n g me a ns t h at t he 
i n divi d u al w as at i m me di ate risk of de at h fr o m 
t he eve nt as it occ urr e d, ie, it d oes n ot i ncl u de 
a n eve nt w hic h hy p ot hetic ally mi g ht h ave 
c a use d de at h h a d it occ urr e d i n a m or e sever e 
f or m. 
b. a n y  p ote ntiall y  si g ht -t hreate ni n g e ve nt or 
per ma ne nt i m pair me nt t o a b o d y str uct ure or a 
b o d y  f u ncti o n. 
c. i n -patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n ge d 
h os pit alizati o n. 
N ote: Pl a n ne d h os pit aliz ati o n f or a 
pre-existi n g c o n diti o n, wit h o ut seri o us 
deteri or ati o n i n he alt h, is n ot c o nsi der e d a 
seri o us a dverse eve nt. I n ge ner al, 
h os pit aliz ati o n si g nifies t h at t he i n divi d u al 
re m ai ne d at t he h os pit al or e mer ge ncy w ar d 
f or o bserv ati o n a n d/ or tr e at me nt ( us u ally 
i nv olvi n g a n over ni g ht st ay) t h at w o ul d n ot 
h ave bee n a p pr o pri ate i n t he p hysici a n's office 
or a n o ut -p atie nt setti n g. C o m plic ati o ns t h at 
occ ur d uri n g h os pit aliz ati o n ar e a dverse 
eve nts. If a c o m plic ati o n pr ol o n gs 
h os pit aliz ati o n or f ulfills a ny ot her seri o us 
criteri a, t he eve nt is seri o us. W he n i n d o u bt as 
t o w het her “ h os pit aliz ati o n ” occ urr e d, t he 
eve nt s h o ul d be c o nsi der e d seri o us. 
d. a me dical or s ur gical i nter ve nti o n t o pre ve nt 
a) or b). 
e. a n y  i n direct har m as a c o nse q ue nce of 
i nc orrect dia g n ostic test res ults w he n use d 
wit hi n ma n ufact urer ’s  i nstr ucti o ns f or use. 
Fetal distress, fetal deat h, or a c o n ge nital a b n or malit y  
or birt h defect. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026656] 
([LOCATION_003]DE)Serious adverse device effect which b y its nature, incidence, 
severit y or outcome has not been identified in the risk 
management file.
Use Error Act or omission of an act that results in a dif ferent medical 
device response than intended by  [CONTACT_69202]. Note: This definition includes slips, lapses, and 
mistakes. An unexpected physiological r esponse of the 
subject does not in its elf constitute a use err or
.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026657]  OF ACRONYMS AND ABBREVIA TIONS
Table2–[ADDRESS_1026658] lenses 
(LID009941)
BCVA Best corrected visual acuity
CE Conformité Européene or European Conformity
CFR Code of Federal Regulations
CI Confidence interval
CRF Case report form
CSM Clinical site manager
CTT Clinical trial team
D Diopter
D/C Discontinue
DC Diopters cy linder
DEP Deviations and evaluability  plan
EOBO Polyxyethylene-polyoxybuty lene
eCRF Electronic case report f orm
EDC Electronic data capture
FAS Full Anal ysis Set
FDA Food and Drug Administration
GCP Good Clinical Practice
IB Investigator’s brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
IEC Independent ethics committee
IP Investigational product
IRB Institutional review board
IRT Interactive response technology
ISO International Organization of Standardization
LCSM Lead clinical site manager
LID Lens identification
min Minute
mm Millimeter
MOP Manual of procedures
N Number
N/A Not applicable
OU Both ey es
PMA Premarket approval
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026659] of 
v ol u nteer s u bjects wit h n or mal e y es ( ot her t ha n c orrecti o n f or refracti ve err or) w h o are at 
least [ADDRESS_1026660] le nses ( A O H G t oric a n d A O t oric) will be e val uate d d uri n g [ADDRESS_1026661] u d y. S u bjects will be ra n d o ml y  assi g ne d i n a 1: [ADDRESS_1026662] le nses t hat were n ot all ocate d f or use i n Per i o d 1 will t he n be assi g ne d per t he 
s pecifie d se q ue nce gr o u p: 
Se q ue nce Gr o u p 
1) A O H G t oric → A O t oric 
2) A O t oric → A O H G t oric 
S u bjects will wear Pair [ADDRESS_1026663] u d y le nses bilaterall y f or a p pr o xi matel y 3 0 mi n. T here 
will be a 3 0 ( + 1 5) mi n was h o ut peri o d bet wee n re m o val of Pair [ADDRESS_1026664] u d y  le nses. 
T he f oll o wi n g assess me nts will be perf or me d m o n oc ularl y i n t he ri g ht a n d left e ye f or Pair 1 
a n d Pair 2 le nses (see secti o n 1 0 f or details) :
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026665] :A O H G t oric le nses 
C o ntr ol Pr o d uct: A O t oric le nses 
P ur p ose a n d 
r ati o n ale T he o verall p ur p ose of t his n o n- dis pe nse st u d y  is t o e val uate t he 
r otati o nal c haracteristics of t he A O H G t oric le ns , b y  assessi n g le ns 
orie ntati o n as t he pri mar y  varia ble c o m pare d t o t he c o m merciall y  
a vaila ble A O t oric le ns. 
Objecti ve(s) T he pri mar y  effecti ve ness o bjecti ve of t his st u d y  is t o 
e v al uate t he perce nta ge of A O H G t oric le nses t hat orie nt 
wit hi n ± 3 0 de grees fr o m t he 9 0° a xis (i deal l ocati o n), 
1 0 mi n after le ns i nserti o n. 
  
 
 
T he safet y o bjecti ve is t o descri be t he safet y pr ofile of t he 
i n vesti gati o nal pr o d ucts t hr o u g h e val uati o n of a d verse 
e ve nts ( A Es), bi o micr osc o p y  fi n di n gs, a n d de vice 
deficie ncies. 
E n d p oi nt(s) Pri mar y  Effecti ve ness 
Perce nt of le nses wit h a xis orie ntati o n wit hi n 
±3 0 de grees fr o m t he 9 0° a xis (i deal l ocati o n ), 1 0 mi n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 3 of 5 4 
after le ns i nserti o n 
Safet y 
A Es 
Bi o micr osc o p yfi n di n gs 
De vice deficie ncies 
Assess me nt(s) Effecti ve ness 
A xis orie ntati o n 1 0 mi n after le ns i nserti o n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 4 of 5 4 
Safet y 
A Es 
Bi o micr osc o p y
De vice Deficie ncies 
St u d y Desi g n T his is a pr os pecti ve, ra n d o mize d, bilateral cr oss o ver , d o u ble -
mas ke d , c o ntr olle d st u d y . S u bject partici pati o n i n t he st u d y  will be 
a p pr o xi matel y  [ADDRESS_1026666] u d y  le ns fr o m t he assi g ne d le ns se q ue nce ( Pair 1) f or 
a p pr o xi matel y  [ADDRESS_1026667] u d y  le ns 
of t he assi g ne d le ns se q ue nce ( Pair 2) bilaterall y f or a p pr o xi matel y  
3 0 mi n. T here will be a 3 0 ( + 1 5) mi n was h o ut peri o d bet wee n 
re m o val of Pair [ADDRESS_1026668] 8 h o urs per da y .
Ke y i ncl usi o n 
criteri a 
( See Secti o n 8. [ADDRESS_1026669] of 
i ncl usi o n criteria) S uccessf ul wear of s oft c o ntact le nses f or visi o n c orrecti o n 
i n b ot h e y es d uri n g t he past 3 m o nt hs f or a mi ni m u m of 
3da y s per wee k a n d 8 h o urs per d a y .
S u bjects m ust ha ve ≥ 0. [ADDRESS_1026670] 
asti g matis m. 
Re q uiri n g c o ntact le ns s p here p o wer fr o m - 0. 5 0 t o - 8. 0 0 D; 
c y li n der p o wer less t ha n or e q ual t o - 2. 2 5 D C; a n d f or 
c y li n der p o wers greater t ha n -1. 0 0 D C, a xis s h o ul d be 
wit h i n ± 3 0 ° fr o m 9 0° or 1 8 0° a xis (i.e., bet wee n 6 0° t o 
1 2 0° or 3 0° t o 1 5 0° i ncl usi ve ). Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 5 of 5 4 
Best s pectacle c orrecte d V A 2 0/ 2 5 or better i n eac h e y e. 
Ke y e xcl usi o n 
criteri a 
( See Secti o n 8. [ADDRESS_1026671] of 
e xcl usi o n criteria) A n y  a nteri or se g me nt i nfecti o n, i nfla m mati o n, or 
a b n or malit y  or disease (i ncl u di n g s ys te mic) t hat 
c o ntrai n dicates c o ntact le ns wear, as deter mi ne d b y t he 
I n vesti gat or. 
Hist or y  of oc ular or i ntra oc ular s ur ger y w hic h c o ntact le ns 
wear c o ul d be c o ntrai n dicate d, as deter mi ne d b y t he 
I n vesti gat or , i ncl u di n g refracti ve s ur ger y a n d/ or irre g ular 
c or nea. 
Bi o micr osc o p y fi n di n gs at baseli ne t hat are m o derate 
( G ra de 3) or hi g her a n d/ or c or neal vasc ularizati o n t hat is 
mil d ( Gra de 2) or hi g her; prese nce of c or neal i nfiltrates 
C urre nt or hist or y  of her petic keratitis i n eit her e ye. 
E y e i nj ur y  wit hi n 1 2 wee ks i m me diatel y  pri or t o e nr olli n g 
i n t his trial. 
Hist or y  of i nt olera nce or h y perse nsiti vit y  t o a n y 
c o m p o ne nt of t he st u d y le nses. 
A n y  cli nicall y  si g nifica nt c or neal t hi n ni n g dis or der s uc h as 
kerat o gl o b us, kerat oc o n us or pell uci d mar gi nal 
de ge nerati o n 
D at a a n al ysis a n d 
s a m ple size 
j ustific ati o n T o a d dress t he pri mar y   effecti ve ness 
e n d p oi nts, c ollecte d 1 0 mi n after le ns i nserti o n, pla n ne d a nal ys es 
are s u m marize d bel o w: 
E n d p oi nt C o m paris o n Statistical Met h o d 
Pri mar y 
Perce nta ge of A O H G 
t oric le nses orie nti n g 
wit hi n ± 3 0 de grees of 
t he 9 0º a xis T hres h ol d = 9 0 % Descri pti ve statistics 
Si nce o nl y  o ne e n d p oi nt will be teste d i nfere ntiall y , t here is n o Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 6 of 5 4 
c o ncer n f or m ulti plicit y . 
N o i nfere ntial testi n g will be carrie d o ut f or safet y e n d p oi nts. 
Sa m ple size calc ulati o n/i nter pretati o n f or pri mar y   
 effecti ve ness e n d p oi nts are s u m marize d bel o w. 
E n d p oi nt Ass u m pti o ns P o wer N
Pri mar y 
Perce nta ge of 
A O H G t o ric 
le nses orie nti n g 
wit hi n 
± 3 0 de grees of 
t he 9 0º a xis N ot a p plica ble  N ot a p plica ble 
9 5 % co nfi de nce 
i nter val f or 
pr o p orti o n will 
e xte n d 0. 1 0 fr o m 
0. 9 0 3 0 
Ke y w or ds H Y D R A G L Y D E 
Asti g matis m 
A xis orie ntati o n 
A O H G t oric 
A O t oric 
Ass oci ate d m ateri als N o le ns care pr o d ucts will be use d. Re- wetti n g dr o ps will n ot be 
per mitte d. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 7 of 5 4 
Ta ble 3 – [ADDRESS_1026672] u d y Pr oce d ur es a n d Assess me nts 
Pr oce d ure/ Assess me nt B aseli ne/ 
Scree ni n g E x p os ure P air 
1 –Peri o d 1 E x p os ure P air 
2 –Peri o d 2 E xit 
I nf or me d C o nse nt  - - -
D e m o gra p hics  - - -
Me dical Hist or y  - - -
C o nc o mita nt Me dicati o ns  - - ()
I ncl usi o n/ E xcl usi o n  - - -
Ha bit ual le ns i nf or mati o n 
( bra n d, p o w er, a xis) *  - - -
V A w/ ha bit ual c orrecti o n 
( S nelle n dista nce) *  - - 
Ma nifest refracti o n *  - - -
B C V A ( S nelle n dista nce 
wit h ma nifest refracti o n) *  - - -
Bi o micr osc o p y # - - 
Fit st u d y le nses -   -
A xis orie ntati o n 1 0 ( + 2) mi n 
after i nserti o n 1 -   -Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 1 8 of 5 4 
Pr oce d ure/ Assess me nt B aseli ne/ 
Scree ni n g E x p os ure P air 
1 –Peri o d 1 E x p os ure P air 
2 –Peri o d 2 E xit 
A d verse E ve nts    
De vice deficie ncies    
E xit F or m () () () 
() if a p plica ble; 
*S o urce o nl y 
 
 
1Data w ill be use d f or deri vi n g pri mar y effecti ve ness e n d p oi nt. 
#PI m a y  c h o ose t o ta ke p h ot o gra p h or vi de o of slit la m p o bser vati o ns 
4P R O T O C O L  A M E N D M E N T S Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026673] be 
a p pr o ve d b y t he I R B/I E C a n d gl o bal a n d re gi o nal Healt h A ut h orities, as a p plica ble, pri or t o 
i m ple me ntati o n e xc e pt w he n re q uire d t o miti gate i m me diate safet y ris ks or w he n t he c ha n ges 
i n v ol ve o nl y  l o gistical or a d mi nistrati ve re visi o ns. 
Page 19of [ADDRESS_1026674] sign 
the approved, revised informed consent (re-consent) , as required b y the IRB/IEC.
4.[ADDRESS_1026675] lenses were introduced into clinical practice over 40 years ago
(Holden 1975) Since then, toric lens technology  has continued to grow, with improvements in 
design, lens formulation, and reproducibility  in order to enhance vision and contac t lens wear 
experience. Patients who do not wish to wear spectacles or undergo refractive surgery for the 
correction of refractive errors may  opt for contact [CONTACT_13276]. Contact [CONTACT_750156] (eg, hy drogel, silicone hy drogel), modality  (daily  wear or extended wear) 
and replacement schedule (dail y disposable, planned replacement, or conventional). All 
contact [CONTACT_750157] .
Alcon launched a monthly replacement lens known as AIR OPTIX for Astigmatism soft 
contact [CONTACT_13276] (AO toric) in 2009. AO toric lenses areindicated for the optical correction of 
astigmatism of up to 6 D in people with healthy  eyes with or without refractive ametropia 
(myopia or hy peropia). AOtoric lenses are made from a fluoro -silicone hy drogel lens 
material consisting of 33% water and 67% lotrafilcon B. When placed on eye, the lenses 
glide over the cornea and serve as a refracting medium to focus light ray s on the retina. These 
lenses use the Precision 8|[ADDRESS_1026676] deposits. The lenses, immersed in phosphate buf fered saline solution, 
are provided sterile in individual blister packs. AO toric lenses carry the European 
Conformity  (CE) -mark and have US FDA  510(k) marketing clearance for daily  wear and 
premarket approval (PMA) fo r extended wear (for up to 6 nights of continuous wear) with 
removal for disposal, or cleaning and disinfection.
Recently , Alcon introduced AI R OPTIX plus HYDRAGLYDE (AOHG sphere ), a spherical 
lens, into the global markets. The AOHG sphere lens is comprise d of the same lotrafilcon B 
material with a packaging saline thatwas designed to incorporate wetting agents for 
improved lens surface wettability , lubricity , and longer lasting lens surface moisture out of 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026677] is to upgrade the packaging saline of commercial AO toric lenses (which 
currentl y consists of isotonic, sodium -phosphate buffered saline) to that currentl y used in the 
AOHG sphere lens .
This non- dispe nse clinical trial will evaluate the on -eye performance of the lotrafilcon B toric 
lens packaged in the AOHG packaging saline (AOHG toric lens).
5.2 Purpose of the Study
The overall purpose of this non -dispense study  is to evaluate the rotational characteristics of 
the AOHG toric lens, b y assessing lens orientation as the primary  variable and comparing it 
to the commerciall y available AO toric lens.
At the end of the study , a clinical study  report will be prepared in accordance with applicable 
regulatory  requirements and standards.
There are no immediate plans to submit the results of this development study  for publication; 
however , the results may  be of fered for publication if they  are of scientific interest, or if the 
results relate to a product that is subsequently  approved or cleared for marketing.
5.[ADDRESS_1026678] lenses may  of
fer improved peripheral vision and the convenience of not wearing
spectacles; however ,this study  will only  use a few select contact [CONTACT_750158]. There is no intended clinical benefit to the 
subject; however , subjects will receive study  visit assessments free of change (that will not 
substitute for a regular eye exam). Material properties and design characteristi cs of AOHG 
toric lenses are features consistent with successful contact [CONTACT_13279] . Based upon nonclinical 
data and documented rationale for applicability  of test results, and clinical and market 
experience with similar contact [CONTACT_750159], AOHG toric lenses are 
assessed to be non -toxic and biocompatible for on -eye use. 
AO toric lenses are indicated for daily and extended wear (up to 6 nights) use; further details 
on any  known potential risks and benefits can be found in the package insert. 
A summary  of the known potential risks and benefits associated with AOHG toric lenses can 
be found in the IB. Any risks to subjects in this trial are minimized by  [CONTACT_13285], and through close sup ervision b y a licensed clinician 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026679] le nses and/or alert site staff for prompt follow -up if there are s ymptoms such 
as ocular discomfort, foreign bod y sensation, excessive tearing, vision changes, or 
hyperemia. 
Refer to the IB for additional information.
6STUDY  OBJECTIVES
6.1 Primary Objective(s)
The overall objective of the study  is to evaluate the rotational characteristics of the AOHG 
toric lens.
Table6–1 Primary Objective(s)
Objective(s) Endpoint(s)
Evaluate the percentage of AOHG toric 
lenses that orient within ± 30 degrees from 
the 90º axis (ideal location), 10 min after 
lens insertionPercent of lenses with axis orientation 
within ±30 degrees from the 90° axis (ideal 
location ), 10 min after lens ins ertion
6.2 Secondary Objective(s)
Not applicable
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Pa ge 2 2 of 5 4 
6. 4 S afet y O bjecti ve(s) 
Ta ble 6 – 3 S afet y O bjecti ve(s) 
O bjecti ve(s) E n d p oi nt(s) 
Descri be t he safet y  pr ofile of t he 
i n vesti gati o nal pr o d ucts AEs 
Bi o micr osc o p y fi n di n gs 
De vice deficie ncies 
7I N V E S TI G A TI O N A L  P L A N 
7. 1 St u d y Desi g n Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026680] of v ol u nteer s u bjects wit h n or mal e y es ( ot her t ha n c orrecti o n f or refracti ve err or) 
w h o are at least [ADDRESS_1026681] le ns weari n g e x perie nce .
S u bjects will be ra n d o ml y assi g ne d i n a 1: [ADDRESS_1026682] le nses t hat 
were n ot all ocate d f or use i n Peri o d 1 will t he n be assi g ne d per t he s pecifie d se q ue nce gr o u p: 
Se q ue nce Gr o u p 
1) A O H G t oric → A O t oric 
2) A O t oric → A O H G t oric 
Page 23of [ADDRESS_1026683]’ s 
participation is approximately  2 hours with approximately  30 minutes of exposure to each 
study  lens.
The study  is expected to take approximately  4 weeks for completion. The study  outline is 
provided in Figure 7 -1 (below):
Figur e 7–1 Flowchart of Study Visit
7.2 Rationale for S
tudy Design
In this study , the on -eye performance of the investigational AOHG toric lens and the 
commerciall y available AO toric lens will be assessed in a prospective, double -masked, 
bilateral crossover design with approximately  30 minutes of exposure to each study  lens.   The 
study  design as well as the exposure duration of study  lenses is supported by  [CONTACT_750160] .
7.3 Rationale for Duration of Treatment/ Follow-Up
The duration of exposure to the investigational products was chosen to address the objective 
of this study , and is aligned with AO toric fitting guidelines forinitial fit assessment 
following lens insertion.
7.[ADDRESS_1026684] to address the study  objectives. Both 
AOHG toric and AO toric lenses are fluoro -silicone hydrogel lenses consisting of 33% water 
and 67% lotrafilcon B , and are prescribed for monthly  wear . AO toric lenses are ind icated for 
the optical correction of astigmatism of up to 6D or less in people with healthy  eyes with or 
without refractive ametropia (my opia or hy peropia).
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Page 24of 54
7.5 Data Monitoring Committee
Not applicable
8STUDY  POPULA TION
The study  population consists of adult male and female subjects (age d 18 and over ) with 
non-diseased ey es, who require optical correction for astigmatism . It is aimed to enroll 
approximately  [ADDRESS_1026685] lens sphere power from 
-0.50 to -8.00 D; cy linder powe r less 
than or equal to -2.25 DC; and for cy linder powers greater than -1.00 DC, axis should be 
between 60° to 120° or 30° to 150° inclusive. Because an approximately  10% screening 
failure rate is expected, approximately  [ADDRESS_1026686] fulfill all of the following criteria:
1. Subject must be at least [ADDRESS_1026687] be able to understand and sign an 
IRB/IEC approved Informed Consent form.
2. Willing and able to attend the sing lestudy  visit as required per protocol.
3. Successful wear of soft contact [CONTACT_750161] [ADDRESS_1026688] ≥ 0.[ADDRESS_1026689] astigmatism.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026690] lens sphere power from - 0.50 to - 8.00 D; cy linder power less than or 
equal to 
-2.25 DC; and for cy linder powers greater than - 1.00 DC, axis should be within 
± 30 ° from 90° or 180° axis (i.e., between 60° to 120° or 30° to 150° inclusive ).
6.Distortion- free keratometric readings at baseline.
7.Best spectacle corrected visual acuity  20/25 or better in each ey e.
8.2 Exclusion C riteria
Subjects fulfilling anyof the following criteria are not eligible for participation in this study .
1. Any anterior segment infection, inflammation, or abnormality  or disease (including 
systemic) that contraindicates contact [CONTACT_13279] , as determined b y the Investigator .
2. Any use of s ystemic or ocular medications for which contact [CONTACT_40057], as determined by  [CONTACT_093] .
3. History  of ocular or intraocular surgery , including refractive surgery  which contact 
[CONTACT_66218], as determined by  [CONTACT_11219]/or irregular 
cornea. 
4. Biomicroscop y findings at baseline that are moderate ( Grade 3) or higher and/or 
corneal vascularization that is mild ( Grade 2) or higher; presence of corneal 
infiltrates
5. Current or history  ofpathologicall y dry eye in either ey e that, in the opi[INVESTIGATOR_684] , would preclude contact [CONTACT_13279] .
6. Current or history  of herpetic keratitis in either eye.
7.Eye injury  within 12 weeks immediately  prior to enrolling in this trial.
8.History  of intolerance or hy persensitivity  to an y component of the study lenses.
9.Any clinically  significant corneal thinning disorder such as keratoglobus, 
keratoconus or pellucid marginal degeneration
10.Enrollment of site staf f or family /household members of the site staf f who are listed 
on the study  personnel log as having a role in the execution of this study .
11.Participation of the subject in a clinical trial within the previous 30 day s or currentl y 
enrolled in an y clinical trial.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026691](s) 
Te st Pr o d uct(s): AI R O P TI X pl us H Y D R A G L Y D E f or Asti g matis m 
s oft c o ntact le nses 
C o ntr ol Pr o d uct(s): AI R O P TI X f or Asti g matis m s oft c o ntact le nses 
Ta ble 9 – [ADDRESS_1026692] 
le nses ( A O H G t oric) -LI D [ADDRESS_1026693] u d y Material: l otrafilc o n B 
Water c o nte nt : 3 3 % 
P o wer ra n ge: 
oS p here: - 1. 0 0 D, - 3. 0 0 D a n d - 5. 0 0 D 
oC y li n der : -1. 2 5 D C 
oA xis a vaila bilit y : 9 0 & 1 8 0 
Base c ur ve ( m m) : 8. 7 m m (tar get) 
Dia meter ( m m) : 1 4. 5 m m (tar get) 
Ot her: A d diti o nal details ca n be f o u n d i n t he I B 
F or m ulati o n Silic o ne H y dr o gel. A d diti o nal details ca n be f o u n d i n t he I B f or 
A O H G t oric. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 2 7 of 5 4 
Usa ge Wear: 
oDail y  Wear f or t his st u d y 
oBilateral 
Re place me nt peri o d: N/ A f or t his n o n -dis pe nse st u d y 
E x p os ure: A p pr o xi matel y 3 0 mi n utes 
Le ns Care: N/ A 
A d diti o nal details ca n be f o u n d i n t he M O P 
N u m ber/ A m o u nt of 
pr o d uct t o be 
pr o vi de d t o t he 
s u bject O ne pair of test st u d y  le nses will be pr o vi de d t o t he s u bject at a 
si n gle visit t o b e w or n f or i n -office use o nl y. The test le nses will be 
re m o ve d after a p pr o xi matel y  [ADDRESS_1026694] me nt le nses are all o we d o nl y  if t here is a de vice deficie nc y  
(e g, t or n le ns). 
Pac ka gi n g 
descri pti o n Blister c o ntai ni n g p h os p hate b uf fere d sali ne s ol uti o n wit h wetti n g 
a ge nts 
La beli n g descri pti o n Le ns F oil la bel i ncl u des: 
-material na me a n d i de ntifier 
-base c ur ve 
-dia meter 
-ma n ufact uri n g pr ot oc ol n u m ber 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pi[INVESTIGATOR_1313] o n date 
-c o nte nt state me nt 
- i n vesti gati o nal de vice state me nt 
-S p o ns or i nf or mati o n 
Pr o vi de d i n b o xes of 4 0 le nses per p o wer per b o x, i de ntifie d 
wit h t he f oll o wi n g: 
- a c ol or c o de d la bel stati n g t he pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal use o nl y  state me nt 
-trac ki n g n u m ber Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026695] ore d at r o o m te m perat ure. 
A d diti o nal 
i nf or mati o n N/ A 
S u p pl y Refer t o t he M O P f or a detaile d descri pti o n 
Ta ble 9–[ADDRESS_1026696](s) AI R O P TI X f or Asti g matis m s oft c o ntact le nses ( A O t oric) 
Ma n ufact urer Alc o n La b orat ories, I nc. 
[ADDRESS_1026697] u d y Material: l otrafilc o n B 
Water c o nte nt: 3 3 % 
P o wer ra n ge: 
oS p here: -1. 0 0 D, -3. 0 0 D a n d - 5. 0 0 D 
oC y li n der: -1. 2 5 D C 
oA xis a vaila bilit y : 9 0 & 1 8 0 
Base c ur ve ( m m): 8. 7 m m (tar get) 
Dia meter ( m m): 1 4. 5 m m (tar get) 
Ot her: A d diti o nal details ca n be f o u n d i n t he I B 
F or m ulati o n Silic o ne H y dr o gel. A d diti o nal details ca n be f o u n d i n t he I B f or A O 
t oric .
Usa ge Wear: 
oDail y  Wear f or t his st u d y 
oBilateral 
Re place me nt peri o d: N/ A f or t his n o n -dis pe nse st u d y Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Pa ge 2 9 of 5 4 
E x p os ure: A p pr o xi matel y  3 0 mi n utes 
Le ns Care: N/ A 
A d diti o nal details ca n be f o u n d i n t he M O P 
N u m ber/ A m o u nt of 
Pr o d uct t o be 
Pr o vi de d t o t he 
s u bject O ne pair of c o ntr ol st u d y le nses will be pr o vi de d t o t he s u bject at a 
si n gle visit t o b e w or n f or i n -office use o nl y. The c o ntr ol le nses will 
be re m o ve d after a p pr o xi matel y  [ADDRESS_1026698] me nt le nses are all o we d o nl y  if t here is a de vice deficie nc y  
(e g, t or n le ns). 
Pac ka gi n g 
descri pti o n Blister c o ntai ni n g p h os p hate b uf fere d sali ne s ol uti o n wit h wetti n g 
a ge nts 
La beli n g descri pti o n Le ns F oil la bel i ncl u des: 
-material na me a n d i de ntifier 
-base c ur ve 
-dia meter 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pi[INVESTIGATOR_1313] o n date 
-c o nte nt state me nt 
- S p o ns or i nf or mati o n 
Pr o vi de d i n b o xes of 6 le nses per p o wer per b o x, i de ntifie d wit h 
t he f oll o wi n g: 
- a c ol or c o de d la bel stati n g t he pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal use o nl y state me nt 
-trac ki n g n u m ber 
St ora ge c o n diti o ns St ore d at r o o m te m perat ure. 
A d diti o nal 
i de ntif y i n g 
i nf or mati o n N/ A 
S u p pl y Refer t o t he M O P f or a detaile d descri pti o n. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
Page 30of 54
9.2 Other Medical Device or Medication Specified for Use During the 
Study
No other medical devices or medications are required to be used in conjunction with the 
investigational products during the clinical study .
9.3 Treatment Assignment / Randomization
Subjects will be randomized in a 1 :1ratio to receive treatment in crossover sequence AOHG 
toric then AO toric or AO toric then AOHG toric , respectivel y.
Only  after signing the ICF , a subject will be assigned a subject number by  [CONTACT_575804] s ystem. 
A randomization list will be generated using a validated sy stem that automates the random 
assignment of treatment arms to randomization numbers in the specified ratio. Subjects will 
be assigned treatment according to the randomization 
list uploaded in the iMedidata 
BALANCE s ystem. The randomization list will be generated and maintained by[CONTACT_750162] .
At Visit 1, all eligible subjects will be randomized via the EDC/I RT integration sy stem to one 
of the lens sequences . The Investigator or delegate will access the respective system after 
confirming that the subject meets all the eligibility  criteria. A randomization number will be 
automatically  assigned to the subject according to the subject randomization list but will not 
be communicated to the site user . The EDC/IR T integration sy stem will inform the site user 
of the treatment assignment to be dispensed to the subject.
9.4 Treatment mask ing
This study  is double -masked, with subjects randomized to use AOHG toric andAO toric
lenses (in a crossover fashion) for the duration of the approx imately  30 minute treatment 
period for each lens pair
. All study  team members (at the site and the Stud y Sponsor) are 
masked to the assigned sequence with the exception of those mentioned in T able 9-3.
Table9–3 Unmasked Individuals Associated with the Study
Unma sked Individual Extent of Unmasking Rationale
Unmasked Study
Coordinator(s)The Unmasked Stud y
Coordinator(s) will manage IP 
inventory , as well as IP 
administration. This individual 
will have access to I P supply , The Unmasked Stud y
Coordinator(s) will be
unmasked to allow for
processing of IP shipment,
storage, and dispensing, as
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026699] y, accountability logs, and 
other documents or supplies 
pertaining to IP accountability . 
This individual monitors 
unmasked and masked study  
data.The CSM will be unmasked
to allow for performance of
IP accountability , 
management of device 
deficiencies and related AE 
lens returns, and an y other 
IP related tasks.
Unmasked Data
Manager(s)The Unmasked Data
Manager(s) will have access to 
restricted fields in RAVE that 
would contain unmasking data.The Unmasked Data
Manager(s) will be 
unmasked to allow for 
review of all restricted data.
IRT Manager The I RT manager will be 
unmasked to allow for s ystem 
programming, testing, and to 
allow for technical oversight of 
the sy stem.The I RT manager is 
unmasked to all aspects of 
the trial for s ystem 
development purposes.
Randomization Specialist The Randomization Specialist 
will be unmasked to allow for 
generation of the randomization 
list and uploading of that list 
into the I RT s ystem.Generates and therefore has 
full knowledge of treatment 
codes but otherwise is 
operati onall y not associated 
with the CTT or an y 
decision making aspects 
related to clinical trial 
design, execution, or 
reporting.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026700] u d y m o nit or f or t he p ur p oses of verif yi n g t he acc o u nti n g of I P  s u p plies. 
A n y  discre pa ncies a n d/ or deficie ncies b et wee n t he o bser ve d dis p ositi o n a n d t he writte n 
acc o u nt m ust be rec or de d al o n g wit h a n e x pla nati o n. All I Ps se nt t o t he I n vesti gat or m ust be 
acc o u nte d f or b y St u d y S p o ns or pers o n nel, a n d i n n o case be use d i n a n u na ut h orize d 
sit uati o n. 
It is t he I n vesti gat or ’s  res p o nsi bilit y  t o e ns ure t hat: 
All st u d y  pr o d ucts are acc o u nte d f or a n d n ot use d i n a n y  u na ut h orize d ma n ner 
All use d f oils a n d u n use d s u p plies are retai ne d b y  desi g nate d u n mas ke d staf f
All u n use d pr o d ucts are a vaila ble f or ret ur n t o t he St u d y S p o ns or , as directe d 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026701] -relate d 
a d verse e ve nt (ie, A D E or S A D E) are ret ur ne d t o t he St u d y  S p o ns or f or i n vesti gati o n , 
u n less ot her wise directe d b y  t he S p o ns or . Refer t o Secti o n [ADDRESS_1026702] u d y , a cc or di n g t o t he i nstr ucti o ns pr o vi de d i n t he M O P . 
Pa ge 3 3 of 5 4 
9. 6 C h a n ges t o c o nc o mit a nt me dic ati o ns, tr e at me nts/ pr oce d ur es 
C ha n ges i n c o nc o mita nt treat me nts d uri n g Vi sit 1are n ot all o we d u nless nee de d f or t he 
pr o per me dical care a n d treat me nt of t he s u bject f or a s peci fic me dical c o n diti o n. 
After t he s u bject is e nr olle d i nt o t he st u d y , t he I n vesti gat or m ust i nstr uct t he s u bject t o n otif y  
t he st u d y  site a b o ut: 
A n y  ne w me dicati o ns 
Alterati o ns i n d ose or d ose sc he d ules f or c urre nt me dicati o ns, 
A n y  me dical pr oce d ure or h o s pi[INVESTIGATOR_1314] o n t hat occ urre d or is pla n ne d 
A n y  n o n- dr u g t hera pi[INVESTIGATOR_014] (i ncl u di n g p h ys ical t hera p y  a n d bl o o d tra nsf usi o ns). 
T he I n vesti gat or m ust d oc u me nt t his i nf or mati o n i n t he s u bject’ s case hist or y  s o urce 
d oc u me nts. 
[ADDRESS_1026703] u d y  le nses bilateral l y  f or 
a p pr o xi matel y  3 0 mi n. T here will be a 3 0 mi n ute ( + 1 5 mi n) was h o ut peri o d bet wee n re m o val 
of Pair [ADDRESS_1026704] u d y pr oce d ures will be c o n d ucte d i n t he f oll o wi n g or der: 
S u bjects will i nsert t he first pair of le nses i n t he ra n d o mize d se q ue nce, bei n g i nstr ucte d 
t o al wa y s be gi n wit h t he ri g ht le ns. 
  
 
  
 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
T he f oll o wi n g assess m e nts will t he n be perf or me d m o n oc ularl y i n t he ri g ht a n d left 
e ye: 
Page 34of [ADDRESS_1026705] read, sign, and date the I RB/IEC -approved informed consent document. The subject 
must sign the I CF BEFORE any  study -specific procedures or assessments can be performed, 
including study -specific screening procedures. Additionall y, have the individual obtaining 
consent from the subject and a witness, if applicable, sign and date the informed consent 
document. 
The Investigator or delegate must provide a cop y of the signed document to the subject and 
place the original signed document in the subject’ s chart, or provide documentation as 
required b y local regulations.
10.[ADDRESS_1026706] 30 day s. Include herbal therapi[INVESTIGATOR_014], vitamins, and all over -the-counter as well as 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026707]’ s partici pati o n, o btai n i nf or mati o n o n a n y  
c ha n ges i n me dical healt h a n d / or t he use of c o nc o mita nt me dicati o ns. 
[ADDRESS_1026708] u d y  I Ps. 
1 0. 2. 4 A d verse E ve nt C ollecti o n: S afet y Assess me nt 
Assess a n d rec or d a n y a d verse e ve nts t hat are o bser ve d or re p orte d, i ncl u di n g t h ose 
ass ociate d wit h c ha n ges i n c o nc o mita nt me dicati o n d osi n g si nce si g nat ure of i nf or me d 
c o nse nt .
1 0. 2. 5 Slit -L a m p Bi o micr osc o p y: S afet y Assess me nt 
S L E of t he c or nea, iris/a nteri or c ha m ber a n d le ns m ust be p erf or me d i n b ot h e y es bef ore 
i nstillati o n of a n y  dia g n ostic e y e dr o ps. 
1 0. 2. 6 De vice Deficie ncies: S afet y Assess me nt 
Assess a n d rec or d a n y De vice Deficie ncies t hat are re p orte d or o bser ve d, i ncl u di n g t h ose 
ass ociate d wit h c ha n ges i n c o nc o mita nt me dicati o n d osi n g si nce e nr oll me nt .Re q uire me nts 
f or re p orti n g de vice deficie ncies i n t he st u d y  ca n be f o u n d i n Secti o n [ADDRESS_1026709] u d y Assess me nts :Effe cti ve ness a n d S afet y 
Assess me nt s
T he f oll o wi n g are a d diti o nal st u d y  assess me nts. Refer t o t he M O P f or f urt her details. 
B C V A ( S nelle n dista nce wit h ma nifest refracti o n) 

A xis orie ntati o n 




Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
 
Pa ge 3 6 of 5 4 




[ADDRESS_1026710] u d y after si g ni n g t he i nf or me d c o nse nt , n ot meeti n g 
i ncl usi o n/e xcl usi o n criteria, a n d pri or t o ra n d o mizati o n t o pr o d uct/ dis pe nse (e x p os ure) of 
st u d y  pr o d uct will be c o nsi dere d a scree n fail ure .
T he I n vesti gat or m ust d oc u me nt t he reas o n f or scree n fail ure i n t he s u bject’ s case hist or y  
s o urce d oc u me nts. 
Su bject n u m bers m ust n ot be re- use d. 
1 0. 4. 2 Disc o nti n u ati o ns Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026711]’ s case hist or y  s o urce d oc u me nts. 
Pa ge [ADDRESS_1026712] a n d, if necessar y , a d vise t he m of a n y t hera pi[INVESTIGATOR_014] a n d/ or me dical pr oce d ures t hat ma y  be 
nee de d t o mai ntai n t heir healt h. 
[ADDRESS_1026713] u d y S p o ns or: 
T he St u d y  S p o ns or m ust: 
oI m me diatel y  n otif y  t he I n vesti gat or(s) a n d s u bse q ue ntl y  pr o vi de 
i nstr ucti o ns f or st u d y  ter mi nati o n. 
oI n f or m t he I n vesti gat or a n d t he re g ulat or y  a ut h orities of t he 
ter mi nati o n/s us pe nsi o n a n d t he reas o n(s) f or t he ter mi nati o n/s us pe nsi o n. 
T he I n vesti gat or (s) m ust: 
oPr o m ptl y  n otif y  t he I R B/I E C of t he ter mi nati o n or s us pe nsi o n a n d of t he 
reas o ns. 
oPr o vi de s u bjects wit h rec o m me n dati o ns f or p ost -st u d y  treat me nt o pti o ns 
as nee de d. 
A n I n vesti gat or ma y  ter mi nate t he site’ s partici pati o n i n t he st u d y  f or reas o na ble ca use. 
[ADDRESS_1026714] u d y p artici p ati o n h as e n de d Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026715] 
clinical signs (including abnormal laboratory  findings) in subjects, users, or other persons, 
whether or not related to the investigational medical device (test article). Refer to the 
Glossary  of Terms and figures below for categories of AEs and SAEs.
Figur e11–1 Categorization of All Adverse Events
Figur e11-2 Categorization of All Serious Adverse
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Pa ge 3 9 of 5 4 
S pecific E ve nts Rele v a nt t o t his Pr ot oc ol 
Seri o us A dverse Eve nts 
I n a d diti o n t o re p orti n g all A E s (seri o us a n d n o n -seri o us) meeti n g t he defi niti o ns, t he 
I n vesti gat or m ust re p ort a n y  occ urre nce of t he f oll o wi n g as a n S A E: 
A n oc ular i nfecti o n i ncl u di n g a pres u me d i nfecti o us ulcer wit h a n y of t he f oll o wi n g 
c haracteristics: 
oCe ntral or parace ntral l ocati o n 
oPe netrati o n of B o w ma n’ s me m bra ne 
oI n filtrates > 2 m m dia meter 
oIritis 
oI n crease i n i ntra oc ular press ure 
oC ult ure p ositi ve f or micr o or ga nis ms 
oI n creasi n g size or se verit y  at s u bse q ue nt ti me p oi nts 
A n y  ce ntral or parace ntral c or neal e ve nt (s uc h as ne o vasc ularizati o n) t hat res ults i n 
per ma ne nt o pacificati o n 
H y p o p y o n 
H y p he ma 
Ne o vasc ularizati o n wit hi n t he ce ntral 6 m m of t he c or nea 
Per ma ne nt visi o n l oss as defi ne d b y l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
t hat fails t o res ol ve 
U veitis (a nteri or , i nter me diate, or p osteri or) 
C or neal a brasi o n affecti n g ≥ 5 0 % of c or ne al s urface area 
Si g nific a nt N o n -Seri o us A dverse Eve nts Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026716] re p ort a n y  occ urre nce of t he f oll o wi n g as a Si g nifica nt 
N o n - Seri o us A d verse E ve nt: 
Pa ge 4 0 of 5 4 
Peri p heral n o n - pr o gressi ve n o n- i nfecti o us ulcers 
All s y m pt o matic c or neal i nfiltrati ve e ve nts 
C or neal stai ni n g sc ore greater t ha n or e q ual t o Gra de 3 ( Refer t o M O P  f or gra di n g 
scales) [ Gra di n g scale is base d u p o n I S O 1 1 9 8 0: 2 0 1 2 u nless s pecifie d differe ntl y  i n 
M O P] 
Te m p orar y  visi o n l oss as defi ne d b y  l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
that persists f or 2 or m ore wee ks 
Ne o vasc ularizati o n sc ore greater t ha n or e q ual t o Gra de 2 ( Refer t o M O P  f or gra di n g 
scales) [ Gra di n g scale is base d u p o n I S O 1 1 9 8 0: 2 0 1 2 u nless s pecifie d differe ntl y  i n 
M O P] 
T he a b o ve e ve nts are base d u p o n t he cate g ories pr o vi de d i n t he I S O 1 1 9 8 0 a n d t he U S F D A  
Pre mar ket N otificati o n ( 5 1 0( k)) G ui da nce D oc u me nt f or Dail y W ear C o ntact Le nses .
Device Deficie ncies 
A de vice deficie nc y  is i na de q uac y  of a me dical de vice wit h res pect t o its i de ntit y , q ualit y , 
d ura bilit y , relia bilit y , safet y , or perf or ma nce. A de vice deficie nc y  ma y  or ma y  n ot be 
ass ociate d wit h patie nt har m (ie, A D E or S A D E); h o we ver , n ot all A D Es or S A D Es are d ue 
t o a de vice deficie nc y . T he I n vesti gat or s h o ul d deter mi ne t he a p plica ble cate g or y liste d i n t he 
De vice Deficie nc y  e C R F f or t he i de ntifie d or s us pect de vice deficie nc y  a n d r e p ort a n y patie nt 
har m se paratel y . E xa m ples of de vice deficie ncies i ncl u de t he f oll o wi n g: 
Fail ure t o meet pr o d uct s pecificati o ns (e g, i nc orrect le ns p o wer/ dia meter/ base 
c ur ve/c ol or) 
Le ns/s ol uti o n cl o u d y
Le ns s urface/e d ge defect 
To r n le ns d uri n g ha n dli n g/i n pac k 
Pac ka gi n g deficit (e g, misla bele d pr o d uct, ta m pere d seal, lea ki n g b ottle/c o ntai ner) 
S us pect pr o d uct c o nta mi nati o n 
Lac k of perf or ma nce 
1 1. 2 M o nit ori n g f or A d verse E ve nts Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026717] has ha d t he o p p ort u nit y  t o s p o nta ne o usl y me nti o n a n y 
pr o ble ms, t he I n vesti gat or s h o ul d i n q uire a b o ut A E s b y  as ki n g t he sta n dar d q uesti o ns: 
Pa ge 4 1 of 5 4 
“ Ha ve y o u ha d a n y healt h pr o ble ms si nce e nr olli n g i n t he st u d y ? ” 
“ Ha ve t here bee n a n y  c ha n ge s i n t he me dici nes y o u ta ke si nce e nr olli n g i n t he st u d y ? ” 
C ha n ges i n a ny pr ot oc ol -s pecific p ar a meters a n d/ or q uesti o n n air es e val uate d d uri n g t he 
st u d y  are t o be re vie we d b y  t he I n vesti gat or . A n y u nt o war d ( u nfa v ora ble a n d u ni nte n de d) 
c ha n ge i n a pr ot oc ol -s pecific p ar a meter or q uesti o n n air e r es p o nse t hat is cli nicall y  rele va nt, 
i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or , is t o be re p orte d as a n A E. T hese cli nicall y  rele va nt 
c ha n ges will be re p orte d re gar dless of ca usalit y .
1 1. 3 Pr oce d ures f or Rec or di n g a n d Re p orti n g 
A Es are c ollecte d fr o m t he ti me of i nf or me d c o nse nt A n y pre -e xisti n g me dical c o n diti o ns or 
si g ns/s y m pt o ms prese nt i n a s u bject pri or t o t he start of t he st u d y  (ie, bef ore i nf or me d 
c o nse nt is si g ne d) are n ot c o nsi dere d A E s i n t he st u d y  a n d s h o ul d be rec or de d i n t he Me dical 
Hist or y  secti o n of t he e C R F .
I n a d diti o n, te m p orar y  le ns a ware ness or vis ual c ha n ges d uri n g t he fitti n g pr ocess are n ot 
c o nsi dere d A E s if t he I n vesti gat or assesses t hat t he s y m pt o m(s) ca n reas o na bl y  res ol ve wit hi n 
t he a ntici pate d a da ptati o n p eri o d. 
F or eac h rec or de d e ve nt, t he A D Es a n d S A Es d oc u me ntati o n m ust i ncl u de: date of 
occ urre nce, se verit y , treat me nt (if a p plica ble), o utc o me, a n d assess me nts of t he seri o us ness 
a n d ca usalit y . I n a d diti o n, t he I n vesti gat or m ust d oc u me nt all de vice defici e ncies re p orte d or 
o bser ve d wit h test a n d c o ntr ol articles o n t he De vice Deficie nc y e C R F . T he site m ust s u b mit 
all a vaila ble i nf or mati o n o n A D Es, S A Es, a n d de vice deficie ncies t o t he St u d y  S p o ns or 
i m me diatel y  as f oll o ws: 
A D Es or S A Es are d oc u me nte d o n t he Seri o us A dverse Eve nt a n d A dverse Device 
Effect e C R F wit hi n 2 4 h o urs of t he I n vesti gat or ’s  or site’ s a ware ness . 
De vice deficie ncies are d oc u me nte d o n t he Device Deficie ncy e C R F wit hi n 2 4 h o urs 
of t he I n vesti gat or ’s  or site’ s a ware ness . 
A pri nte d c o p y of t he c o m plete d Seri o us A dverse Eve nt a n d A dverse Device Effect 
a n d / or Device Deficie ncy e C R F m ust be i ncl u de d wit h pr o d uct ret ur ns. 
A d diti o nal rele va nt i nf or mati o n after i nitial re p orti n g m ust be e ntere d i nt o t he e C R F as 
s o o n as t he data bec o me a vaila ble. 
D oc u me nt a n y c ha n ges t o c o nc o mita nt me dicati o ns o n t he a p pr o priate e C R Fs. 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 4 9 9 P r o t o c o l  -  C l i n i c a l 1 7- N o v- 2 0 1 7 
D oc u me nt all rele va nt i nf or mati o n fr o m Disc har ge S u m mar y , A ut o ps y  Re p ort, 
Pa ge 4 2 of 5 4 
Certificate of Deat h ,etc, if a p plica ble, i n narrati ve secti o n of t he Seri o us A dverse 
Eve nt a n d A dverse Device Effect e C R F .
N ote: S h o ul d t he E D C s yste m bec o me n o n - o perati o nal, t he site m ust c o m plete t he 
a p pr o priate pa per Seri o us A dverse Eve nt a n d A dverse Device Effect a n d/ or Device Deficie ncy 
F or m. T he c o m plete d f or m is e maile d t o t he St u d y S p o ns or t o 
acc or di n g t o t he ti meli nes o utli ne d a b o ve; h o we ver , t he 
re p orte d i nf or mati o n m ust be e ntere d i nt o t he E D C s y ste m o nce it bec o mes o perati o nal. 
St u d y  S p o ns or re prese ntati ves ma y  be c o ntac te d f or a n y  pr ot oc ol relate d q uesti o n a n d t heir 
c o ntact i nf or mati o n is pr o vi de d i n t he Ma n ual of Pr oce d ures t hat acc o m pa nies t his pr ot oc ol. 
F urt her , de pe n di n g u p o n t he nat ure of t he A E or de vice deficie nc y  bei n g re p orte d, t he St u d y  
S p o ns or ma y  re q uest c o pi[INVESTIGATOR_1309] a p plica ble p orti o ns of t he s u bject’ s me dical rec or ds. T he 
I n vesti gat or m ust als o re p ort all A E s a n d de vice deficie ncies t hat c o ul d ha v e le d t o a S A D E 
acc or di n g t o t he re q uire me nts of re g ulat or y  a ut h orities or I R B/I E C. 
I nte nsit y a n d C a us alit y Assess me nts 
W here a p pr o priate, t he I n vesti gat or m ust assess t he i nte nsit y  (se verit y) of t he A E base d u p o n 
me dical j u d g me nt wit h c o nsi derati o n of a n ys u bjecti ve s y m pt o m(s), as defi ne d bel o w: 
I nte nsity ( Severity) 
Mil d A n A E is mil d if t he s u bject is a ware of b ut ca n easil y  t olerate t he si g n or 
s y m pt o m. 
M o derate A n A E is m o derate if t he si g n or s y m pt o m res ults i n disc o mf ort si g nifica nt 
e n o u g h t o ca use i n terfere nce wit h t he s u bject’ s us ual acti vities. 
Se vere A n A E is se vere if t he si g n or s y m pt o m is i nca pacitati n g a n d res ults i n t he 
s u bject’ s i na bilit y  t o w or k or e n ga ge i n t heir us ual acti vities. 
F or e ver y  A E i n t he st u d y , t he I n vesti gat or m ust assess t he ca usalit y ( Relate d or N ot Relate d 
t o t he me dical de vice or st u d y  pr oce d ure). A n assess me nt of ca usalit y  will als o be perf or me d 
b y  St u d y  S p o ns or utilizi n g t he sa me defi niti o ns, as s h o w n bel o w: 
C a us ality Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026718] u d y  
Page 43of 54
procedure has not been demonstrated, but there is a reasonable possibility  that 
the AE was caused by  [CONTACT_13303] y procedure.
NotRelated An AE classified as not related may  either be definitely  unrelated or simply  
unlikely  to be related (ie, there are other more likely  causes for the AE).
The Study  Sponsor will assess the AEs and may  upgrade the Investigator ’s assessment of 
serious ness and/or causality . The Study  Sponsor will notify  the Investigator of an y AEs that is 
upgraded from non -serious to serious or from unrelated to related .
11.[ADDRESS_1026719] information are provided in the MOP  that 
accompanies this protocol.
Alcon products associated with device deficiencies and/or product related AEs must be 
returned and must include the Complaint # which will be provided by  [CONTACT_13304] ’sGlobal Product Complaint Management Sy stem 
(GPCMS).
11.5 Unmask ing of the Study Treatment
Masked information on the identity  of the assigned medical device should not be disclosed 
during the stud y (See Section 9.4) . If the treatment code needs to be broken in the interest of 
subject safet y, the Investigator is encouraged to contact [CONTACT_749624]. Dependent upon 
the individual circumstances (ie, medical emergency), the c ode may  be broken prior to 
contact [CONTACT_69211] . The Stud y Sponsor must be informed of all cases in which 
the code was broken and of the circumstances involved. Additionally , the Study  Sponsor may  
be required to unmask the information in order to fulfill expedited regulatory reporting
requirements .
11.6 Follow -Up of Subjects with Adverse Events
The Investigator is responsible for adequate and safe medical care of subjects during the 
study  and for ensuring that appropriate medical care and relevant follow -up procedures are 
maintained after the study . 
The Investigator should provide the Study  Spon sor with any  new safet y information (which 
includes new AEs and changes to previousl y reported AEs) that may  affect the safet y 
evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Page 44of 54
study , any  additional information rec eived at follow -up should be documented in the eCRFs 
up to study  completion (ie, database lock). 
Any additional data received up to 1month after subject discontinuation or exit must be 
documented and available upon the Study  Sponsor ’s request. All compla ints received after 
this time period will be considered and processed as spontaneous (following the post -market 
vigilance procedures) and should be communicated to the medical device’ s manufacturer as 
per local requirements.
The Investigator should alsoreport complaints on non- Alcon products directly  to the 
manufacturer as per the manufacturer ’s instructions or local regulatory  requirements
.
11.7 Pregnancy in the Clinical Study
Women of childbearing potential or women who are pregnant at the time of study  entry are 
not excluded from participation. Pregnancy  should be included in the Medical History  section 
of the eCRF when a pregnant woman enters the study .Pregnancy  is not reportable as an AE; 
however , complications may  be reportable and will be decided on a ca se–by-case basis.
12ANAL YSIS PLAN
Continuous variables will be summarized using the number of observations, mean, standard 
deviation (SD), median, minimum and maximum, as well as confidence intervals (CI) or 
confidence limits where applicable. Categorical va riables will be summarized with counts 
and percentages from each category .Any deviations to the analysis plan will be updated 
during the course of the study  as part of a protocol amendment or will be detailed in the 
clinical study  report
.
12.[ADDRESS_1026720] be determined prior to breaking the code for masked lens 
sequence assignment and locking the database, based upon the Deviations and Evaluability  
Plan.
12.2 Analysis Sets
12.2.1 Safety Analysis Set
Safety  anal yses will be c onducted using the safet y anal ysis set on a treatment- emergent basis.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
Page 45of 54
As such, the safety  anal ysis set will include all subjects/eyes exposed to any stud y lenses
evaluated in this study . For treatment -emergent safety anal yses, subjects/eyes will be
categor ized under the actual study  lenses exposed in the corresponding lens sequence .
12.2.2 Full Analysis Set
The full anal ysis set (F AS) is the set of all randomized subjects who are exposed to any  study
lenses evaluated in this study .
12.2.3 Per Protocol Analysis Set
The per protocol (PP) analy sis set is a subset of F AS and excludes all data/subjects which 
have met an y of the critical deviation or evaluability criteria identified in the DEP .
12.3 Demographic and Baseline Characteristics
Demographic and baseline characteristics will be summarized by  [CONTACT_271460]. 
Counts and percentages will be presented for categorical variables such as sex, age group, 
race, and ethnicity . N, mean, SD, median, minimum, and maximum will be presented for 
continuous variables such as ag e.
12.4 Effectiveness Analyses
This study  defines 1 primary ,  effectiveness 
endpoints. All ef fectiveness evaluations will use the F AS as the primary  analy sis set. 
Supportive analy ses of the primary   effectiveness endpoints will be 
conducted using the PP  Analysis Set onl y if the number of subjects excluded from the PP
Analy sis Set exceeds 5% of the F AS.
12.4.1 Analysis of Primary Effectiveness Endpoint(s)
The primary  endpoint is the percent of AOHG toric with axis orientation within ±30 degrees 
from the 90° axis (ideal location), 10 min after lens insertion. This percentage is calculated 
for the binary  variable derived based on axis location of each lens, as defined below:
Yes –if the absolute dif ference between the axis location and 90 is less than or equal 
to 30 (ie, lens axis locat edbetween the 60°and 120 °axisinclusive )
No –otherwise
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017

Page 46of 54
[IP_ADDRESS] Statistical Hypotheses
Noinferences are to be made on the primary  effectiveness endpoint; therefore no h ypotheses 
are formulated. 
[IP_ADDRESS] Analysis Methods
Frequency  and percentage of lenses classified as ‘Y es’ will be provided for AOHG toric and 
AO toric, and a two -sided CI  will be calculated. 
A threshold of 90% (as a minimum) has been established for this endpoint based upon 
historical data. Therefore, percent of ‘Y es’ for AOHG toric lenses will be compared 
numericall y to 90%.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017

Pa ge 4 7 of 5 4 
1 2. 5 H a n dli n g of Missi n g D at a 
All data o btai ne d i n e val ua ble s u bjects/e y es will be i ncl u de d i n t he a nal y sis. N o i m p utati o n 
f or missi n g val ues will be carrie d o ut f or t he pri mar y   ef fecti ve ness 
a nal ys es .
1 2. 6 S afet y A n al ys es 
T he safet y e n d p oi nts are: 
A d verse e ve nts 
Bi o micr osc o p yFi n di n g 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026721] signs informed consent to study  exit will be 
accounted for in the reporting. Safety  anal yses will be conducted using the safet y analysis set 
on a treatment -emergent basis. Descriptive summaries (counts and percentages) for ocular 
and nonocular AEs w ill be presented by  [CONTACT_750163]. AEs leading to study  discontinuation, significant non-serious AEs, and 
SAEs will be identified. Individual subject listings will be provided, as necessary . 
Individual subjec t listings will be provided for AEs that occur after signing informed consent 
but prior to exposure to IP.
Each biomicroscop y parameter will be tabulated by [CONTACT_13296]. For each biomicroscop y 
parameter , counts and percentages of ey es that experience an incr ease of ≥ 2 grades from 
baseline ( Baseline / Screening assessment time point during V isit 1 ) to subsequent assessment 
at the Exit will be presented. A supportive listing will be generated which will include all 
biomicroscopy  data from all assessment time p oints for these ey es experiencing the increase.
Two listings (prior to exposure of stud y lenses and treatment -emergent) of device 
deficiencies, as recorded on the Device Deficiency Form, will be provided. Additionally , each 
device deficiency  category  will be tabulated.
No inferential testing will be done for safet y anal ysis.
12.[ADDRESS_1026722] an interim anal ysis and no criteria b y which the study would be 
terminated early based upon statistical determination
12.8 Sample Size Justification
Although inferential testing is not planned for the primary  effectiveness endpoint, expected 
precision of the observed results is provided. A two-sided 95% confidence interval for a 
single proportion will extend approximately  0.10 from the observed value when the expected 
proportion is 0.90, with a sample size of 30.
 
 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026723]’ s anony mity is maintained throughout the 
course of the stud y. In particular , the Investigator must keep an enroll ment log with 
confidential identify ing information that corresponds to the subject numbers and initials of 
each stud y participant. At the end of the clinical study , the Study  Sponsor will collect a copy  
of the enrollment log without any identifying subject information . All documents submitted 
to the Study  Sponsor will identify  the subjects exclusively  by [CONTACT_69213]. No other personally  identify ing information will be transmitted to the Study  
Sponsor .
The Study  Sponsor may  release anony mized study data to external researchers for purposes 
of future research directly  related to the study  objectives, or future research that is bey ond the 
scope of the current study objectives. The Informed Consent Form explains this to study  
subjects. Anonymization means that all identifiable information will be removed from the 
dataset and all links to the subjects in the study will be removed. Anon ymization of the data 
will maintain confidentiality  of the subjects who participate in the study  so that the y cannot 
be identified b y external researchers. The anon ymized data set will contain records from all 
of the subjects in the current study , but the anonymization process might change the data set 
in some way s, so external researchers will be informed that they might not be able to 
duplicate some o f the results from this study .
13.[ADDRESS_1026724] and are accessible for verification by  [CONTACT_25007] , 
and all discrepancies shall be appropriately  documented via the query  resolution process. Site
monitors are appointed by [CONTACT_119013] y Sponsor and are independent of stud y site staf f.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026725]: 
S u bject i de ntificati o n ( na me, se x, race/et h nicit y) 
D oc u me ntati o n of s u bject eli gi bilit y 
Date of i nf or me d c o nse nt 
Dates of visits 
D oc u me ntati o n t hat pr ot oc ol s pecific pr oce d ures were perf or me d 
Res ults of st u d y  para meters, as re q uire d b y t he pr ot oc ol 
I P  acc o u nta bilit y  rec or ds 
D oc u me ntati o n of A Es a n d ot her safet y para meters (if a p plica ble) 
Rec or ds re gar di n g me dical hist ories a n d t he use of c o nc o mita nt t hera pi[INVESTIGATOR_258755] t o a n d 
d uri n g t he st u d y
Date of st u d y c o m pleti o n a n d reas o n f or earl y disc o nti n uati o n, if a p plica ble 
It is re q uire d t hat t he a ut h or of a n e ntr y i n t he s o urce d o c u me nts be i de ntifia ble. Direct access 
t o s o urce d oc u me ntati o n ( me dical rec or ds) m ust be all o we d f or t he p ur p ose of verif y i n g t hat 
t he data rec or de d o n t he C R F are c o nsiste nt wit h t he ori gi nal s o urce data. 
O nl y  desi g nate d i n di vi d uals at t he site will c o m pl ete t he C R Fs. T he C R Fs m ust be c o m plete d 
at re g ular i nter vals f oll o wi n g t he cli nical st u d y  visit sc he d ule. I t is e x pecte d t hat all data 
re p orte d ha ve c orres p o n di n g e ntries i n t he s o urce d oc u me nts. T he Pri nci pal I n vesti gat or is 
res p o nsi ble f or re vie wi n g a n d certif y i n g t hat t he C R Fs are acc urate a n d c o m plete. T he o nl y 
s u bject i de ntifiers rec or de d o n t he C R Fs will be s u bject n u m ber , a n d s u bject de m o gra p hic 
i nf or mati o n. 
1 3. 3 D at a Re vie w a n d Cl arific ati o ns Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026726]’ s s o urce data will be c o m plete d b y t he site m o nit or t o 
e ns ure c o m plete ness a n d acc urac y . After t he C R Fs ha ve bee n c o m plete d, a d diti o nal data 
clarificati o ns a n d/ or a d diti o ns ma y  be nee de d as a res ult of t he data clea ni n g pr ocess. Data 
clarificati o ns are d oc u me nte d a n d are part of eac h s u bject’ s C R F .
Page 51of [ADDRESS_1026727] the appropriate site visits at the 
appropriate intervals according to the stud y monitoring plan. The clinical investigation will 
be monitored to ensure that the rights and well -being of the subjects are protected, the 
reported data are accurate, complete, and verifiable from the source documents, and the study 
is conducted in compliance with the current approved protocol (and amendments[s], if 
applicable), with current GCP , and with applicable regulatory  requirements.
The site may  not screen subjects or perform the informed consent process on any  subject until 
it receive sa notification from an appropriate Study Sponsor representative that the si te may  
commence conducting study  activities. Monitoring will be conducted periodically  while the 
clinical study  is ongoing. Monitoring methods may  include site visits, telephone, written and 
fax correspondence. Close -out visits will take place after the last visit of the last subject at the 
site.
A Coordinating Investigator [INVESTIGATOR_69200]. In cases where a Coordinating Investigator [INVESTIGATOR_69201] , the Study  
Sponsor will select the Coordinati
ng Investigator based upon their experience, qualifications, 
active study  participation, and their willingness and ava ilability  to take on this role.
Additionally , Alcon may  have an expert Alcon Observer present during the planned study  
visit to make techn ical observations during the visit. The assessments made by  [CONTACT_750164](s) will be considered optional and will not impact subject evaluability . The 
Investigator and the Alcon Observer(s) will make and record their observations separatel y.
The Alcon Observer must be supervised by  [CONTACT_750165]’s presence or activities do not bias the outcome of the stud y, affect the quality of 
the research data, and/or compromise the rights and welfare of the subjec t. The Alcon
Observer will not intervene with the standard of care provided to study  subjects or make 
safet y-related decisions or assessments. The activities of Alcon Observer(s) will be described 
in the I CF.
The Alcon Observer(s) will perform a technical assessment through the biomicroscope of
each treatment pair of contact [CONTACT_13276], on some or all subjects, using the investigative site’s
biomicroscope (slit -lamp). The Alcon O bserver will remain masked to the investigational 
product until after database lock . The Alcon Observer will record general observations 
related to lens fit and surface characteristics made during the slit -lamp examination onto a 
eCRF in a separate database with access onl y provided to internal Alcon personnel.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026728] u d y S p o ns or a n d t he I n vesti gat or ’s  files will be re vie we d as part of t he 
o n g oi n g st u d y m o nit ori n g. Fi na ncial i nf or mati o n is t o be ke pt se paratel y. 
A d diti o nall y , t he I n vesti gat or m ust kee p st u d y rec or ds a n d s o urce d oc u me nts c o nsiste nt wit h 
t he ter ms of t he cli nical st u d y  a gree me nt wit h t he St u d y  S p o ns or . If t he I n vesti gat or retires, 
rel ocates, or f or a n y ot her reas o n wit h dra ws fr o m res p o nsi bilit y  of kee pi n g t he st u d y  rec or ds, 
t he n t he St u d y  S p o ns or m ust be n otifie d a n d s uita ble arra n ge me nts ma de f or rete nti o n of 
st u d y  rec or ds a n d s o urce d oc u me nts nee de d t o c o m pl y  wit h nati o nal a n d i nter nati o nal 
re g ulati o ns. 
[ADDRESS_1026729] u d y  S p o ns or 
wit h t he I n vesti gat or/I nstit uti o n a n d a n y  ot her parties i n v ol ve d i n t he cli nical st u d y  will be 
pr o vi de d i n writi n g as part of t he pr ot oc ol or as a se parate a gree me nt. 
[ADDRESS_1026730] be c o n d ucte d i n acc or da nce wit h t he et hical pri nci ples c o ntai ne d 
wit hi n: 
T he D eclarati o n of H e lsi n ki , a n d i n c o m plia nce wit h t he I C H E 6 G C P  C o ns oli date d 
G ui deli ne, I S O 1 4 1 5 5: 2 0 1 1, a n d t he a p plica ble U S F D A  2 1 C F R Re g ulati o ns. 
S O Ps of t he St u d y  S p o ns or a n d c o ntract researc h or ga nizati o ns partici pati n g i n t he 
c o n d uct of t he cli nical st u d y  a n d all ot her a p plica ble re g ulati o ns. 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026731] u d y  i n 
c o m plia nce wit h t he pr ot oc ol. De viati o ns fr o m t his pr ot oc ol, re g ulat or y  re q uire me nts a n d/ or 
G C P  m ust be rec or de d a n d re p orte d t o t he S p o ns or pri or t o data base l oc k. If nee de d, 
Page 53of [ADDRESS_1026732] 
be approved b y an IRB/IEC. The Investigator must provide documentation of the I RB/IEC 
approval to the Study  Sponsor . The approval must be dated and must identify the applicable 
protocol, am endments (if any), informed consent form, assent form (if any ), all applicable 
recruiting materials, written information for subject, and subject compensation programs. The 
IRB/IEC must be provided with a copy of the IB, package insert for AO toric, an y periodic 
safet y updates, and all other information as required by [CONTACT_13308]/or the I RB/IEC. 
At the end of the study , the Investigator must notify  the IRB/IEC about the study ’s 
completion. The IRB/IE C also must be notified if the study  is terminate d prematurel y. 
Finally , the Investigator must report to the I RB/IEC on the progress of the study  at intervals 
stipulated by  [CONTACT_1201]/IEC.
Voluntary  informed consent must be obtained in writing from every subject and the process 
shall be documented before an y procedure specific to the clinical investigation is applied to 
the subject. The Investigator must have a defined process for obtaining consent. Specifically , 
the Investigator , or their delegate, must explain the clinical study  to each potential subject a nd 
the subject must indicate voluntary  consent by  [CONTACT_40071]. The subject must be provided an opportunity to ask questions of the 
Investigator , and if required by  [CONTACT_1295], other qualified personnel. The I nvestigator 
must provide the subject with a cop y of the consent form written in a language the subject 
understands. The consent document must meet all applicable local laws and provide subjects 
with information regarding the purpose, procedures, requiremen ts, and restrictions of the 
study , along with any  known risks and potential benefits associated with the IP  and the study , 
the available compensation, and the established provisions for maintaining confidentiality  of 
personal, protected health information. Subjects will be told about the voluntary  nature of 
participation in the study  and must be provided with contact [CONTACT_40072] . The subject also must be told 
that their reco rds may  be accessed b y appropriate authorities and Sponsor -designated 
personnel. The Investigator must keep the original, signed cop y of the consent 
(file in 
subject’ s medical records ) and must provide a duplicate cop y to each subject according to 
local re gulations. 
The Study  Sponsor assures that the key  design elements of this protocol will be registered on 
www .clinicaltrials.gov as required b y current regulations and, if applicable, other public 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-[ADDRESS_1026733] u dies 
I S O 1 1 9 8 0: [ADDRESS_1026734] le ns care pr o d ucts -
G ui da nce f or cli nical i n vesti gati o ns 
I S O 1 4 1 5 5: [ADDRESS_1026735] u dies 
2 1 C F R Part 1 1 - Electr o nic Rec or ds; Electr o nic Si g nat ures 
2 1 C F R Part 5 0 -Pr otecti o n of H u ma n S u bjects 
2 1 C F R Part 5 6 - I nstit uti o nal Re vie w B oar ds 
2 1 C F R Part 8 1 2 - I n vesti gati o nal De vice E xe m pti o ns 
2 1 C F R Par t 5 4 -Fi na ncial Discl os ure b y Cli nical I n vesti gat ors 
T he Calif or nia Bill of Ri g hts 
[ADDRESS_1026736] u d y Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - [ADDRESS_1026737] J O pt o m. 1 9 7 5 A u g; 5 8: 2 7 9 - 9 9. 
                                                                                                                
                                                                                     
Date/Time 
(mm/dd/yyyy GMT): Signed by: [CONTACT_13310] :
11/17/2017 20:37:29
11/17/2017 20:04:07
11/17/2017 19:51:36
11/17/2017 19:45:30
11/17/2017 19:45:30
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: [CONTACT_13277]:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054499
Protocol - Clinical
17-Nov-2017
